STXBP1 and Encephalopathy: The trial, launched in July 2025, aimed to assess CAP-002 gene therapy in children with syntaxin-binding protein 1 (STXBP1) encephalopathy, a condition characterized by abnormal brain function and recurrent seizures (https://clinicaltrials.gov/study/NCT06983158) (Table S1).